Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as brinzolamide 1% ophthalmic suspension
brinzolamide 1% · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Azopt 1% ophthalmic suspension | ACTIVE_COMPARATOR | Ophthalmic suspension |
| Brinzolamide 1% ophthalmic suspension | EXPERIMENTAL | ophthalmic suspension |
| Name | Type | Description |
|---|---|---|
| brinzolamide 1% ophthalmic suspension | DRUG | brinzolamide 1% ophthalmic suspension |
| Azopt 1% | DRUG | Azopt 1%, RLD |
Inclusion Criteria: * Male and females 18 years of age or older, * diagnosed with primary open-angle glaucoma or ocular hypertension. Exclusion Criteria: * Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Brinzolamide 1% is an ophthalmic suspension used to treat glaucoma, specifically open angle glaucoma, and ocular hypertension. It is a small molecule carbonic anhydrase inhibitor that lowers intraocular pressure when applied to the eye. The drug is being developed by Bausch + Lomb Corporation under the ticker BLCO.
Brinzolamide 1% works by inhibiting the enzyme carbonic anhydrase 2 (CA2). This inhibition reduces the production of aqueous humor in the ciliary body of the eye, which in turn lowers intraocular pressure. Lowering intraocular pressure is the primary goal in managing glaucoma and ocular hypertension to prevent optic nerve damage.
Brinzolamide 1% is developed by Bausch + Lomb Corporation, which trades under the ticker symbol BLCO. The company is responsible for the clinical development and potential commercialization of this ophthalmic suspension.
Brinzolamide 1% is in Phase 3 clinical development. It has not been approved by the FDA and remains an investigational product. The Phase 3 program includes completed trials evaluating its therapeutic equivalence and safety in patients with glaucoma or ocular hypertension.
Brinzolamide 1% has been studied in two completed clinical trials: NCT03896633, a Phase 1 therapeutic equivalence study with 637 participants, and NCT01722604, a Phase 3 therapeutic equivalence study with 258 participants. Both trials enrolled adults with open angle glaucoma or ocular hypertension in the United States.
Yes, brinzolamide 1% is also known as brinzolamide 1% ophthalmic suspension. The two names refer to the same product, which is a small molecule carbonic anhydrase inhibitor formulated as an eye drop for the treatment of glaucoma and ocular hypertension.